生物医药国际研发态势专刊 |
|
|
|
|
全球融合蛋白药物研发态势分析 * |
李东巧1,陈芳1,CynthiaLiu2,YingzhuLi2,YiDeng2,韩涛1,余敏2,杨艳萍1,***(),王学昭1,***() |
|
引用本文:
李东巧,陈芳,CynthiaLiu,YingzhuLi,YiDeng,韩涛,余敏,杨艳萍,王学昭. 全球融合蛋白药物研发态势分析 *[J]. 中国生物工程杂志, 2019, 39(5): 22-34.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I5/22
|
[1] |
Drugs@FDA: FDA Approved Drug Products-Enbrel, U.S.Food and Drug Administration. [2019-04-04]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103795
|
[2] |
Elonva, European Medicines Agency. [2010-02-26]. https://www.ema.europa.eu/en/medicines/human/EPAR/elonva
|
[3] |
Drugs@FDA: FDA Approved Drug Products-Idelvion, U.S.Food and Drug Administration. [2019-04-04]. https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm489212.htm
|
[4] |
Drugs@FDA: FDA Approved Drug Products-Eylea, U.S.Food and Drug Administration. [2019-04-04]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125387
|
[5] |
EP Vantage 2018 Preview.[ 2018-09-05]. http://info.evaluategroup.com/rs/607-YGS-364/images/EPV18Prev.pdf
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|